Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints three independent directors

Robert Bertolini, Matthew Emmens and Theodore Samuels join the board

Bristol-Myers Squibb has appointed three independent directors to its board, temporarily expanding its membership until the firm's annual meeting elections on 2 May.

Robert Bertolini brings strategic and operational leadership experience from Bausch & Lomb, where he recently served as president and chief financial officer prior to the company's sale to Valeant.

He also brings expertise from Schering-Plough, where he was executive vice president and chief financial officer, and over 20 years of corporate finance experience from PricewaterhouseCoopers.

Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors.

Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief executive and chairman at Shire, president of Merck KGaA's pharmaceutical division, and president and chief executive of AstraZeneca and Merck & Co's joint venture, Astra Merck.

Samuels also brings considerable business and operational experience to the position, with a particular expertise in economics, capital markets and investment decision-making.

He currently serves as a director at Perrigo Company and Stamps.com, and is the former president of Capital Guardian Trust Company, and global equity portfolio manager at Capital Group.

Lamberto Andreotti, chairman of the board at BMS, said: “I am pleased to welcome Bob, Matt and Ted to the board, and know that their unique skill sets and experience will be invaluable to the company going forward.

“As I announced in December, I will be retiring as chairman, effective 2 May 2017. I am happy to be leaving with such a strong board in place and am confident Bristol-Myers Squibb has a bright future.”

23rd February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics